Epithelial plasticity in prostate cancer: Principles and clinical perspectives

Rajdeep Das; Philip A. Gregory; Brett G. Hollier; Wayne D. Tilley; Luke A. Selth

doi:10.1016/j.molmed.2014.09.004

Epithelial plasticity in prostate cancer: Principles and clinical perspectives

Rajdeep Das
, Philip A. Gregory
, Brett G. Hollier
, Wayne D. Tilley
, Luke A. Selth

Research output: Contribution to journal › Review article › peer-review

22 Citations (Scopus)

Abstract

Over the past decade, the capacity of cancer cells to oscillate between epithelial and mesenchymal phenotypes, termed epithelial plasticity (EP), has been demonstrated to play a critical role in metastasis. This phenomenon may be particularly important for prostate cancer (PC) progression, since recent studies have revealed interplay between EP and signaling by the androgen receptor (AR) oncoprotein. Moreover, EP appears to play a role in dictating the response to therapies for metastatic PC. This review will evaluate preclinical and clinical evidence for the relevance of EP in PC progression and consider the potential of targeting and measuring EP as a means to treat and manage lethal forms of the disease.

Original language	English
Pages (from-to)	643-651
Number of pages	9
Journal	Trends in Molecular Medicine
Volume	20
Issue number	11
DOIs	https://doi.org/10.1016/j.molmed.2014.09.004
Publication status	Published - 1 Nov 2014
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Androgen deprivation therapy
Androgen receptor
Chemotherapy
Epithelial plasticity
Epithelial-mesenchymal transition
Mesenchymal-epithelial transition

Access to Document

10.1016/j.molmed.2014.09.004Licence: In Copyright

Cite this

@article{8279fdc0af644b00a12bae1b431751da,

title = "Epithelial plasticity in prostate cancer: Principles and clinical perspectives",

abstract = "Over the past decade, the capacity of cancer cells to oscillate between epithelial and mesenchymal phenotypes, termed epithelial plasticity (EP), has been demonstrated to play a critical role in metastasis. This phenomenon may be particularly important for prostate cancer (PC) progression, since recent studies have revealed interplay between EP and signaling by the androgen receptor (AR) oncoprotein. Moreover, EP appears to play a role in dictating the response to therapies for metastatic PC. This review will evaluate preclinical and clinical evidence for the relevance of EP in PC progression and consider the potential of targeting and measuring EP as a means to treat and manage lethal forms of the disease.",

keywords = "Androgen deprivation therapy, Androgen receptor, Chemotherapy, Epithelial plasticity, Epithelial-mesenchymal transition, Mesenchymal-epithelial transition",

author = "Rajdeep Das and Gregory, \{Philip A.\} and Hollier, \{Brett G.\} and Tilley, \{Wayne D.\} and Selth, \{Luke A.\}",

year = "2014",

month = nov,

day = "1",

doi = "10.1016/j.molmed.2014.09.004",

language = "English",

volume = "20",

pages = "643--651",

journal = "Trends in Molecular Medicine",

issn = "1471-4914",

publisher = "Elsevier B.V.",

number = "11",

}

TY - JOUR

T1 - Epithelial plasticity in prostate cancer

T2 - Principles and clinical perspectives

AU - Das, Rajdeep

AU - Gregory, Philip A.

AU - Hollier, Brett G.

AU - Tilley, Wayne D.

AU - Selth, Luke A.

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Over the past decade, the capacity of cancer cells to oscillate between epithelial and mesenchymal phenotypes, termed epithelial plasticity (EP), has been demonstrated to play a critical role in metastasis. This phenomenon may be particularly important for prostate cancer (PC) progression, since recent studies have revealed interplay between EP and signaling by the androgen receptor (AR) oncoprotein. Moreover, EP appears to play a role in dictating the response to therapies for metastatic PC. This review will evaluate preclinical and clinical evidence for the relevance of EP in PC progression and consider the potential of targeting and measuring EP as a means to treat and manage lethal forms of the disease.

AB - Over the past decade, the capacity of cancer cells to oscillate between epithelial and mesenchymal phenotypes, termed epithelial plasticity (EP), has been demonstrated to play a critical role in metastasis. This phenomenon may be particularly important for prostate cancer (PC) progression, since recent studies have revealed interplay between EP and signaling by the androgen receptor (AR) oncoprotein. Moreover, EP appears to play a role in dictating the response to therapies for metastatic PC. This review will evaluate preclinical and clinical evidence for the relevance of EP in PC progression and consider the potential of targeting and measuring EP as a means to treat and manage lethal forms of the disease.

KW - Androgen deprivation therapy

KW - Androgen receptor

KW - Chemotherapy

KW - Epithelial plasticity

KW - Epithelial-mesenchymal transition

KW - Mesenchymal-epithelial transition

UR - https://www.scopus.com/pages/publications/84909589374

U2 - 10.1016/j.molmed.2014.09.004

DO - 10.1016/j.molmed.2014.09.004

M3 - Review article

C2 - 25262538

AN - SCOPUS:84909589374

SN - 1471-4914

VL - 20

SP - 643

EP - 651

JO - Trends in Molecular Medicine

JF - Trends in Molecular Medicine

IS - 11

ER -

Epithelial plasticity in prostate cancer: Principles and clinical perspectives

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this